Eli Lilly's Retatrutide: 25% Weight Loss in Phase 3 Trial! | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest breakthroughs and trends shaping the landscape of medicine and treatment. In the realm of weight management and metabolic disorders, significant advancements are underway. Roche and Zealand Pharma have moved Petrelintide, an amylin analog, into a Phase 3 clinical trial after a promising Phase 2 showing a nearly 10% weight loss in...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharma and BioTech Daily
Bayer's $2.2B Ohio Site Boosts U.S. Pharma | Pharma and Biotech Daily
Novartis's $7.8B mRNA Deal with Abogen | Pharma and Biotech Daily
Sanofi's $1B Deal with Regeneron: Immunology Breakthroughs | Pharma and Biotech Daily
AstraZeneca's $2B Oncology Investment | Pharma and Biotech Daily
Get summaries like this every morning.
Free AI-powered recaps of Pharma and BioTech Daily and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.